Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials

Venous thromboembolism (VTE) is a common cause of morbidity and mortality in cancer patients. Until recently, guidelines recommended the use of low-molecular weight heparin (LMWH) as standard of care for VTE in patients with cancer. Despite the proven efficacy of direct oral anticoagulants (DOACs) for treatment of VTE, there is equipoise supporting their use in cancer patients.

https://www.heartlungcirc.org/article/S1443-9506(21)01349-4/fulltext?rss=yes

Source: Heart, Lung and Circulation - December 9, 2021 Category: Cardiology Authors: Alexandra C. Murphy, Anoop N. Koshy, Omar Farouque, Belinda Yeo, Jaishankar Raman, Leighton Kearney, Matias B. Yudi Tags: Original Article Source Type: research